公开(公告)号：US12281103B2

公开(公告)日：2025-04-22

申请号：US18397454

申请日：2023-12-27

Applicant: Ardelyx, Inc.

Inventor： Dean Dragoli ,  Irina Dotsenko ,  Jason Lewis

IPC: C07D403/14 ,  A61K47/55 ,  A61P1/00 ,  A61P1/10 ,  A61P3/12 ,  A61P9/04 ,  A61P9/12 ,  A61P29/00 ,  C07D241/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D487/08

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

公开(公告)号：US20210163524A1

公开(公告)日：2021-06-03

申请号：US16636596

申请日：2018-08-06

Applicant: Ardelyx, Inc.

Inventor： Gary Luehr ,  Dean Dragoli ,  Michael Leadbetter ,  Tao Chen ,  Jason Lewis

IPC: C07J63/00 ,  A61P5/44

Abstract: The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used to treat hyperkalemia.

公开(公告)号：US20250067907A1

公开(公告)日：2025-02-27

申请号：US18823388

申请日：2024-09-03

Applicant: Ardelyx, Inc.

Inventor： Gary Luehr ,  Dean Dragoli ,  Michael Leadbetter ,  Tao Chen ,  Jason Lewis

IPC: G02B3/00 ,  A61P5/44 ,  C07J63/00 ,  G02B5/02 ,  G02F1/1335

Abstract: The present invention provides a compound of formula (I) or a salt thereof: wherein X, L, V, R1, R2, R3 and R4, are as defined herein.

公开(公告)号：US10385024B2

公开(公告)日：2019-08-20

申请号：US16007622

申请日：2018-06-13

Applicant: Ardelyx, Inc.

Inventor： Noah Bell ,  Christopher Carreras ,  Dominique Charmot ,  Tao Chen ,  Michael Leadbetter ,  Jeffrey Jacobs ,  Jason Lewis

IPC: C07D217/18 ,  C07D401/14 ,  C07D217/14 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  A61K47/60 ,  A61K47/55

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

公开(公告)号：US20240209019A1

公开(公告)日：2024-06-27

申请号：US18518267

申请日：2023-11-22

Applicant: ARDELYX, INC.

Inventor： Dean Dragoli ,  Gary Luehr ,  Tao Chen ,  Jason Lewis ,  Michael Leadbetter

IPC: C07J63/00 ,  A61K31/56 ,  A61K31/58 ,  A61P3/12 ,  A61P5/40

CPC classification number: C07J63/008 ,  A61K31/56 ,  A61K31/58 ,  A61P3/12 ,  A61P5/40

Abstract: The present invention provides a compound of formula (I) or a salt thereof:




wherein X, L, V, R1, R2, R3 and R4, are as defined herein.

公开(公告)号：US11858959B2

公开(公告)日：2024-01-02

申请号：US17429599

申请日：2020-02-06

Applicant: ARDELYX, INC.

Inventor： Dean Dragoli ,  Gary Luehr ,  Tao Chen ,  Jason Lewis ,  Michael Leadbetter

IPC: C07J63/00 ,  A61P3/12 ,  A61K31/56 ,  A61P5/40 ,  A61K31/58

CPC classification number: C07J63/008 ,  A61K31/56 ,  A61K31/58 ,  A61P3/12 ,  A61P5/40

Abstract: The present invention provides a compound of formula (I) or a salt thereof: (Formula (I)) wherein X, L, V, R1; R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) and as a result are useful in the treatment of hyperkalemia by preventing cortisol from being oxidised to cortisone and thus allowing it to occupy the mineralocorticoid receptor, thus stimulating potassium excretion.

公开(公告)号：US11768319B2

公开(公告)日：2023-09-26

申请号：US16636596

申请日：2018-08-06

Applicant: Ardelyx, Inc.

Inventor： Gary Luehr ,  Dean Dragoli ,  Michael Leadbetter ,  Tao Chen ,  Jason Lewis

IPC: C07J63/00 ,  A61P5/44 ,  G02B5/02 ,  G02B5/20 ,  G02B3/00 ,  G02F1/1335 ,  G02B27/00

CPC classification number: G02B5/0294 ,  A61P5/44 ,  C07J63/008 ,  G02B3/0056 ,  G02B5/0215 ,  G02B5/201 ,  G02B27/0018 ,  G02F1/133502 ,  G02B5/021 ,  G02B2207/123 ,  G02F1/133526

Abstract: The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used to treat hyperkalemia.

公开(公告)号：US11147884B2

公开(公告)日：2021-10-19

申请号：US16476835

申请日：2018-01-09

Applicant: Ardelyx, Inc.

Inventor： Irina Dotsenko ,  Dean Dragoli ,  Jason Lewis

IPC: A61K47/55 ,  A61P3/12 ,  A61P1/10 ,  A61P9/12 ,  C07D401/12 ,  C07D401/14

Abstract: The present disclosure is directed to compounds (I′) and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (I′) and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (I′) and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

公开(公告)号：US20230273354A1

公开(公告)日：2023-08-31

申请号：US18101009

申请日：2023-01-24

Applicant: Ardelyx, Inc.

Inventor： Gary Luehr ,  Dean Dragoli ,  Michael Leadbetter ,  Tao Chen ,  Jason Lewis

IPC: G02B5/02 ,  G02B5/20 ,  G02B3/00 ,  G02F1/1335 ,  G02B27/00 ,  A61P5/44 ,  C07J63/00

CPC classification number: G02B5/0294 ,  G02B5/201 ,  G02B3/0056 ,  G02F1/133502 ,  G02B5/0215 ,  G02B27/0018 ,  A61P5/44 ,  C07J63/008 ,  G02B5/021 ,  G02B2207/123 ,  G02F1/133526

Abstract: The present invention provides a compound of formula (I) or a salt thereof:




wherein X, L, V, R1, R2, R3 and R4, are as defined herein.

公开(公告)号：US20220106354A1

公开(公告)日：2022-04-07

申请号：US17429599

申请日：2020-02-06

Applicant: ARDELYX, INC.

Inventor： Dean Dragoli ,  Gary Leuhr ,  Tao Chen ,  Jason Lewis ,  Michael Leadbetter

IPC: C07J63/00 ,  A61P3/12

Abstract: The present invention provides a compound of formula (I) or a salt thereof: (Formula (I)) wherein X, L, V, R1; R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) and as a result are useful in the treatment of hyperkalemia by preventing cortisol from being oxidised to cortisone and thus allowing it to occupy the mineralocorticoid receptor, thus stimulating potassium excretion.